|
Gene: OSBPL8 |
Gene summary for OSBPL8 |
Gene summary. |
Gene information | Species | Human | Gene symbol | OSBPL8 | Gene ID | 114882 |
Gene name | oxysterol binding protein like 8 | |
Gene Alias | MST120 | |
Cytomap | 12q21.2 | |
Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q5HYM3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
114882 | OSBPL8 | CA_HPV_1 | Human | Cervix | CC | 1.79e-06 | -2.16e-01 | 0.0264 |
114882 | OSBPL8 | CCI_2 | Human | Cervix | CC | 4.99e-06 | 6.05e-01 | 0.5249 |
114882 | OSBPL8 | CCII_1 | Human | Cervix | CC | 1.09e-10 | -6.13e-01 | 0.3249 |
114882 | OSBPL8 | Tumor | Human | Cervix | CC | 9.77e-19 | -5.28e-01 | 0.1241 |
114882 | OSBPL8 | sample1 | Human | Cervix | CC | 2.03e-03 | -4.83e-01 | 0.0959 |
114882 | OSBPL8 | sample3 | Human | Cervix | CC | 1.24e-14 | -4.38e-01 | 0.1387 |
114882 | OSBPL8 | H2 | Human | Cervix | HSIL_HPV | 1.14e-08 | -3.61e-01 | 0.0632 |
114882 | OSBPL8 | L1 | Human | Cervix | CC | 9.00e-09 | -4.87e-01 | 0.0802 |
114882 | OSBPL8 | T1 | Human | Cervix | CC | 1.19e-11 | -5.14e-01 | 0.0918 |
114882 | OSBPL8 | T3 | Human | Cervix | CC | 4.72e-14 | -4.21e-01 | 0.1389 |
114882 | OSBPL8 | LZE4T | Human | Esophagus | ESCC | 8.60e-18 | 5.71e-01 | 0.0811 |
114882 | OSBPL8 | LZE5T | Human | Esophagus | ESCC | 5.94e-05 | 4.97e-01 | 0.0514 |
114882 | OSBPL8 | LZE7T | Human | Esophagus | ESCC | 2.61e-06 | 5.05e-01 | 0.0667 |
114882 | OSBPL8 | LZE8T | Human | Esophagus | ESCC | 3.13e-04 | -8.14e-03 | 0.067 |
114882 | OSBPL8 | LZE20T | Human | Esophagus | ESCC | 1.54e-05 | 1.61e-01 | 0.0662 |
114882 | OSBPL8 | LZE22D1 | Human | Esophagus | HGIN | 2.06e-06 | 7.18e-02 | 0.0595 |
114882 | OSBPL8 | LZE22T | Human | Esophagus | ESCC | 3.02e-04 | 2.21e-01 | 0.068 |
114882 | OSBPL8 | LZE24T | Human | Esophagus | ESCC | 4.02e-14 | 3.84e-01 | 0.0596 |
114882 | OSBPL8 | LZE21T | Human | Esophagus | ESCC | 7.15e-08 | 3.09e-01 | 0.0655 |
114882 | OSBPL8 | LZE6T | Human | Esophagus | ESCC | 6.73e-06 | 1.20e-01 | 0.0845 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
GO:00454445 | Cervix | CC | fat cell differentiation | 53/2311 | 229/18723 | 3.72e-06 | 9.75e-05 | 53 |
GO:19016538 | Cervix | CC | cellular response to peptide | 72/2311 | 359/18723 | 1.89e-05 | 3.48e-04 | 72 |
GO:00512713 | Cervix | CC | negative regulation of cellular component movement | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
GO:00400133 | Cervix | CC | negative regulation of locomotion | 76/2311 | 391/18723 | 3.47e-05 | 5.60e-04 | 76 |
GO:20001463 | Cervix | CC | negative regulation of cell motility | 71/2311 | 359/18723 | 3.47e-05 | 5.60e-04 | 71 |
GO:00303363 | Cervix | CC | negative regulation of cell migration | 68/2311 | 344/18723 | 5.11e-05 | 7.70e-04 | 68 |
GO:00434349 | Cervix | CC | response to peptide hormone | 77/2311 | 414/18723 | 1.40e-04 | 1.70e-03 | 77 |
GO:00713757 | Cervix | CC | cellular response to peptide hormone stimulus | 57/2311 | 290/18723 | 2.32e-04 | 2.59e-03 | 57 |
GO:00328698 | Cervix | CC | cellular response to insulin stimulus | 42/2311 | 203/18723 | 4.95e-04 | 4.83e-03 | 42 |
GO:00518964 | Cervix | CC | regulation of protein kinase B signaling | 39/2311 | 185/18723 | 5.25e-04 | 5.10e-03 | 39 |
GO:00518973 | Cervix | CC | positive regulation of protein kinase B signaling | 28/2311 | 120/18723 | 5.90e-04 | 5.59e-03 | 28 |
GO:00434913 | Cervix | CC | protein kinase B signaling | 43/2311 | 211/18723 | 5.95e-04 | 5.60e-03 | 43 |
GO:00328688 | Cervix | CC | response to insulin | 50/2311 | 264/18723 | 1.28e-03 | 1.02e-02 | 50 |
GO:00108834 | Cervix | CC | regulation of lipid storage | 15/2311 | 57/18723 | 3.13e-03 | 2.05e-02 | 15 |
GO:00082865 | Cervix | CC | insulin receptor signaling pathway | 25/2311 | 116/18723 | 3.59e-03 | 2.30e-02 | 25 |
GO:00347645 | Cervix | CC | positive regulation of transmembrane transport | 40/2311 | 219/18723 | 6.97e-03 | 3.76e-02 | 40 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OSBPL8 | SNV | Missense_Mutation | rs191644576 | c.2555N>A | p.Arg852Gln | p.R852Q | Q9BZF1 | protein_coding | tolerated(0.59) | benign(0.043) | TCGA-FP-A9TM-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
OSBPL8 | SNV | Missense_Mutation | c.1382N>A | p.Arg461His | p.R461H | Q9BZF1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-HU-8243-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
OSBPL8 | SNV | Missense_Mutation | novel | c.17N>T | p.Ala6Val | p.A6V | Q9BZF1 | protein_coding | tolerated_low_confidence(0.98) | benign(0.025) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
OSBPL8 | insertion | Frame_Shift_Ins | novel | c.1401dupA | p.Trp468MetfsTer8 | p.W468Mfs*8 | Q9BZF1 | protein_coding | TCGA-BR-4256-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
OSBPL8 | insertion | Frame_Shift_Ins | novel | c.1989_1990insGAGCTACAGAA | p.Lys664GlufsTer9 | p.K664Efs*9 | Q9BZF1 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |